The urgent need for tests and therapeutics has brought companies together and pushed researchers to work at breakneck speeds.

Digital biomarkers of cognitive decline could alert us to the early stages of dementia before irreversible damage occurs.

There’s a new cell-based cancer immunotherapy on the block.

The US lacks standardized methods to assess products for potency and safety. That’s a big problem for the labs tasked with doing the testing.

The midwestern state has quietly laid the groundwork for a biotech hub.

Finding new tenants for former drug development sites isn’t always easy. But a new, thriving industry has materialized to do just that.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

Insulin-producing cells grown in the lab could offer a functional cure for the disease.

The pharmaceutical industry is looking to machine learning to overcome complex challenges in drug development.